Filter
293
Text search:
rifampicin
Featured
Recommendations
37
New Publications
66
Language
Document type
No document type
192
Guidelines
39
Studies & Reports
27
Manuals
14
Fact sheets
8
Strategic & Response Plan
7
Training Material
3
Situation Updates
2
App
1
Countries / Regions
Western and Central Europe
25
India
19
Eastern Europe
15
South Africa
9
Nepal
7
Germany
7
Kenya
5
Bangladesh
5
Nigeria
4
Philippines
4
Cambodia
4
Rwanda
4
Malawi
4
Namibia
4
Ukraine
4
Myanmar / Burma
4
South–East Asia Region
4
Ethiopia
3
Tanzania
3
Latin America and the Carribbean
3
Asia
3
Tajikistan
3
Russia
3
Ghana
2
Uganda
2
Zambia
2
Colombia
2
Africa
2
Global
2
Sierra Leone
1
Pakistan
1
Afghanistan
1
Mozambique
1
Benin
1
Eswatini/ Swaziland
1
Brazil
1
Ecuador
1
Lesotho
1
Sri Lanka
1
Eastern Europe and Central Asia
1
Paraguay
1
Bhutan
1
Turkmenistan
1
Authors & Publishers
Publication Years
Category
Countries
96
Clinical Guidelines
43
Public Health
8
Pharmacy & Technologies
7
Women & Child Health
5
Key Resources
4
Capacity Building
1
Toolboxes
TB
138
HIV
25
NTDs
18
AMR
15
Pharmacy
10
Refugee
8
Polio
4
Caregiver
4
Conflict
3
Global Health Education
2
Ebola & Marburg
1
Mental Health
1
COVID-19
1
2.0 Rapid Response
1
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral
...
Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub5.
In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive
...
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are need
...
The objective of the study was the validation and implementation of GeneXpert MTB/RIF for routine use in the rapid detection of tuberculosis and sensitivity to rifampicin in clinical samples; for this, 1592 respiratory samples were collected and ana
...
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama
...
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi
...
This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Mozambique.
BMC Infectious Diseases (2016) 16:423 DO
...
Patients with retreatment tuberculosis (TB) represent those
who have been treated previously for onemonth ormorewith
anti-TB drugs and who have been diagnosed once again with
the disease.These patientsmainly include relapses, treatment
after failure, or loss to follow-up on a first-line treatmen
...
12 countries have a high TB estimated burden with an incidence rate more than 45 per 100 000 population They represent 88 of the cases in the Region
In 2019 the TB case detection gap in the Region was 52 500 cases
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB,
...
Epidemiologisches Bulletin; 22. August 2016 / Nr. 33 ;DOI 10.17886/EpiBull-2016-050
